THIS HAS A FLOAT UNDER 4M & A MARKET CAP UNDER 8M ! ! !
HILS IS ON THE MOVE CLOSING GREEN 8 OUT OF THE LAST 10
RECENT COLLABORATION ALLOWS HILLSTREAM TO ENTER THE RAPIDLY GROWING IMMUNO-ONCOLOGY THERAPEUTICS MARKET
Hello Everyone,
Did you get our last profile? It closed green that day and again 6 of the next 7 sessions. We kicked off January with a 25% overnight winner and it has been all gravy since then. Most of our profiles have gone on to move double digits from the opening trade the days we brought them to you. Let’s hope that February is another quality month.
The markets certainly are erratic right now as evidenced by today’s big spike on the Nasdaq and small pullback on the Dow. It is hard to make heads or tails of what’s going on. No matter what state the market is in there are always opportunities worth researching.
This next one has been on the move since the second half of January. The company put news out the other day and as you can see the stock went nuts.
There is no doubt that HILS is on the move closing green 8 out of the last 10. One of the factors that could be playing a major part in HILS recent success is it’s structure itself. Yahoo has the Market cap under 8M and a float under 4M. It moved another 7% today even after the huge session it had on the 31st with well over 100M exchanging hands on the session. I LIKE THAT.
MAJOR NEWS from Tuesday is still in play and circulating:
HILLSTREAM BIOPHARMA SIGNS AN EXCLUSIVE OPTION AGREEMENT TO ADVANCE NEXT-GENERATION ANTI-MUC1-C AGENTS FOR DRUG RESISTANT CANCERS
Development expected to capitalize upon tumor targeting Quatramers™
MUC1-C could be effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC), small cell lung cancer (SCLC), merkel cell carcinoma (MCC) and neuroendocrine prostate cancer (NEPC)
BRIDGEWATER, N.J., Jan. 31, 2023 (GLOBE NEWSWIRE) — Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced signing an exclusive option agreement with Dana-Farber Cancer Institute to license technology targeting the MUC1-C oncoprotein.
The MUC1 gene was identified by Dr. Donald Kufe, Distinguished Physician and Researcher at Dana-Farber and based on its overexpression in human cancers. Dr. Kufe’s long-standing work has supported the premise that prolonged activation of MUC1-C in settings of chronic inflammation promotes cancer.
Dr. Kufe has demonstrated that MUC1-C is necessary for multiple hallmarks of the cancer cell, including (i) the persister cell (PC) state, (ii) drug resistance, (iii) immunosuppression, and (iv) poor clinical outcomes. Importantly, he has found a marked MUC1-C dependency for cancer stem cells (CSCs) derived from highly aggressive TNBCs, SCLCs, MCCs and NEPCs. Based on these findings, MUC1-C has emerged as an exceptional target for cancer treatment with agents developed in the Kufe laboratory.
Dana-Farber has granted under an exclusive option agreement to Hillstream Biopharma Inc., certain of its proprietary technology which if converted to an exclusive license agreement, will allow Hillstream to develop anti-MUC1-C antibodies to selectively deliver Hillstream’s Quatramer-based lead candidate HSB-1216 targeting CSC by the induction of ferroptosis. This approach combining HSB-1216 with conjugation to MUC1-C antibodies is highly synergistic for the elimination of CSCs, which is needed for long term responses and cures.
“We look forward to this unique opportunity to work with Dr. Kufe and Dana-Farber,” said Randy Milby, CEO of Hillstream. “This agreement allows Hillstream to leverage our Quatramer platform to advance anti-MUC1-C agents targeting CSCs for the treatment of highly aggressive tumors, which represents a major unmet need for patients.”
Please Read the Full Profile Here: https://insiderfinancial.com/hils1/
Sincerely,
No comments:
Post a Comment